Literature DB >> 7718516

Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes.

W C Rowan1, G Hale, J P Tite, S J Brett.   

Abstract

The CAMPATH-1 (CD52) antigen is a 21-28 kDa glycopeptide which is highly expressed on lymphocytes and macrophages and is coupled to the membrane by a glycosylphosphatidylinositol (GPI) anchoring structure. The function of this molecule is unknown. However, it is an extremely good target for complement-mediated attack and antibody-mediated cellular cytotoxicity. The humanized CAMPATH-1H antibody, which is directed against CD52, is very efficient at mediating lymphocyte depletion in vivo, and is currently being used in clinical trials for lymphoid malignancy and rheumatoid arthritis. It is therefore important to examine the functional effects of this antibody on different lymphocyte sub-populations. Because several other GPI-linked molecules expressed on the surface of T lymphocytes are capable of signal transduction resulting in cell proliferation, we have investigated whether the CAMPATH-1 antigen can also mediate these effects. In the presence of phorbol esters and cross-linking anti-Ig antibodies, mAbs specific for CD52 induced proliferation and lymphokine production in highly purified resting CD4+ and CD8+ T lymphocytes. The rat IgG2c YTH 361.10 anti-CD52 antibody, however, was able to activate resting CD4+ and CD8+ T cells directly without cross-linking or phorbol myristate acetate in the absence of Fc-bearing cells. Anti-CD52 antibodies also augmented the anti-CD3 mediated proliferative response of CD4+ and CD8+ T cells when the two antibodies were co-immobilized onto the same surface or cross-linked in solution by the same second antibody. Both CD4+ CD45RA and CD4+ CD45RO T cells were stimulated to proliferate by anti-CD52 antibodies in the presence of appropriate co-stimulatory factors. Anti-CD52 mAbs did not, however, synergize with anti-CD2 or CD28 mAb to induce CD4+ T cell proliferation. The activation of CD4+ T cells by anti-CD52 antibodies was inhibited by cyclosporin A, suggesting a role for the calcineurin-dependent signal transduction pathways. Although CD52 could transduce a signal in T cells, anti-CD52 antibodies did not inhibit antigen-specific or polyclonal T cell responses, suggesting this molecule does not play an essential co-stimulatory role in normal T cell activation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7718516     DOI: 10.1093/intimm/7.1.69

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  29 in total

Review 1.  Promising approaches in acute leukemia.

Authors:  J Cortes; H M Kantarjian
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

Review 2.  Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy.

Authors:  Carsten Denkert; Silvia Darb-Esfahani; Sibylle Loibl; Ioannis Anagnostopoulos; Korinna Jöhrens
Journal:  Semin Immunopathol       Date:  2011-04-17       Impact factor: 9.623

3.  Regulation unmasked by activation.

Authors:  Mike Clark; Anne Cooke
Journal:  Nat Immunol       Date:  2013-07       Impact factor: 25.606

4.  Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro.

Authors:  Evis Havari; Michael J Turner; Juanita Campos-Rivera; Srinivas Shankara; Tri-Hung Nguyen; Bruce Roberts; William Siders; Johanne M Kaplan
Journal:  Immunology       Date:  2014-01       Impact factor: 7.397

5.  [Alemtuzumab: a further option for treatment of multiple sclerosis].

Authors:  T Menge; B C Kieseier; C Warnke; O Aktas; H-P Hartung
Journal:  Nervenarzt       Date:  2012-04       Impact factor: 1.214

Review 6.  The immunological function of CD52 and its targeting in organ transplantation.

Authors:  Yang Zhao; Huiting Su; Xiaofei Shen; Junfeng Du; Xiaodong Zhang; Yong Zhao
Journal:  Inflamm Res       Date:  2017-03-10       Impact factor: 4.575

7.  Microdomain-dependent regulation of Lck and Fyn protein-tyrosine kinases in T lymphocyte plasma membranes.

Authors:  S Ilangumaran; S Arni; G van Echten-Deckert; B Borisch; D C Hoessli
Journal:  Mol Biol Cell       Date:  1999-04       Impact factor: 4.138

8.  Favorable effects of alemtuzumab on allospecific regulatory T-cell generation.

Authors:  Josh Levitsky; Joseph R Leventhal; Joshua Miller; Xuemei Huang; Li Chen; Dhivya Chandrasekaran; Anat R Tambur; James M Mathew
Journal:  Hum Immunol       Date:  2011-11-23       Impact factor: 2.850

9.  Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.

Authors:  M G Wing; T Moreau; J Greenwood; R M Smith; G Hale; J Isaacs; H Waldmann; P J Lachmann; A Compston
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

10.  T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10.

Authors:  Esther Bandala-Sanchez; Yuxia Zhang; Simone Reinwald; James A Dromey; Bo-Han Lee; Junyan Qian; Ralph M Böhmer; Leonard C Harrison
Journal:  Nat Immunol       Date:  2013-05-19       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.